Transition from IBD Audit to IBD Registry
In 2016 the national IBD audit is coming to an end, and the IBD Registry is becoming the vehicle for the biological therapies audit and quality improvement programme. Teams can participate using a choice of data entry systems including some local systems they may have in their hospital already.
The IBD Registry provides the infrastructure to capture pseudonymised IBD patient data and link it with routinely collected NHS hospital statistics. Bringing this data together for the first time will:
- Drive continuous improvement in patient care and access to care across the UK
- Inform commissioning and service design
- Improve our understanding of long term outcomes
- Provide local, regional & national data in order to better define the pattern of ulcerative colitis and Crohn’s disease
- Support IBD research
Being part of the IBD Registry will give participating teams access to better local data to manage their biologics patients and IBD service more effectively, while patients, clinicians and the NHS will all benefit from national audit of the safety and appropriate use of biologics and biosimilars. In time, the combined UK data will become a unique resource for real-world clinical effectiveness and health economic studies in IBD care.
The audit and Registry teams are working closely to manage the transition and you can find a list of frequently asked questions here:
FAQs on IBD programme transition to Registry
NHS England’s Quality Accounts
The IBD Registry’s IBD Biologics Audit was part of NHS England’s Quality Accounts programme for 2017/18 and has been included in the programme for 2018/19. You can read more about NHS England’s Quality Accounts here.
Find out more about:
We’re looking for a motivated and organised Operations Manager to lead on management of our ongoing service operations and our new projects stream, as well as the information governance and general compliance that underpins both of these. Our ongoing service...read more
The IBD Registry is inviting IBD clinical teams across the UK to participate in a post-marketing safety study of patients using biosimilar Zessly (infliximab). This study is facilitated by the Registry on behalf of Sandoz Ltd, the manufacturer of Zessly. The purpose...read more
The IBD Registry is delighted a presentation prepared by the Registry’s Analytics Hub at the University of Liverpool featured in the British Society of Gastroenterology Annual Meeting in Glasgow. The Audit of biological therapy for IBD - Shawihdi et al Poster BSG 2019...read more
The IBD Registry says the launch of the new IBD Standards, the first for six years, at the BSG Annual meeting in Glasgow today, Thursday, 20th June, will provide a catalyst to drive quality in inflammatory bowel disease (IBD). The IBD Standards, produced by IBD UK, an...read more
Continuing its mission to improve the care that people with IBD receive, the Royal College of Physicians is offering IBD teams an opportunity to participate in a new quality improvement collaborative, consisting of three 1-day learning sessions and supported action...read more